Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 10:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 7,883 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Carbohydrates Clear all
Completed Phase 2 Interventional Results available

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

NCT00691015
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
rituximab, busulfan, carmustine, cyclophosphamide, cytarabine, etoposide, fludarabine phosphate, melphalan, total body irradiation (TBI), anti-thymocyte globulin IV
Biological · Drug · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 18, 2026, 10:26 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

NCT03850535
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Idasanutlin, Cytarabine, Daunorubicin, Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 18, 2026, 10:26 PM EDT
Completed Phase 4 Interventional

Brain Perfusion & Oxygenation in Parkinson's Disease With NOH

NCT03229174
View directory record Official record
Conditions
Parkinson Disease, Neurogenic Orthostatic Hypotension
Interventions
Droxidopa, Placebo
Drug
Lead sponsor
William Ondo, MD
Other
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Oct 18, 2026, 10:26 PM EDT
Completed Early Phase 1 Interventional

Methotrexate and Etoposide Infusions Into the Fourth Ventricle in Children with Recurrent Posterior Fossa Brain Tumors

NCT02905110
View directory record Official record
Conditions
Brain Tumor Recurrent
Interventions
Methotrexate, Etoposide, Ommaya Reservoir
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Year to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 18, 2026, 10:26 PM EDT
Terminated Not applicable Interventional

Prevention of Parenteral Nutrition-Associated Cholestasis With Cyclic Parenteral Nutrition in Infants

NCT01062815
View directory record Official record
Conditions
Cholestasis, Prematurity, Gastroschisis, Intestinal Atresia, Necrotizing Enterocolitis
Interventions
Parenteral Nutrition
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
Up to 7 Days
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Oct 18, 2026, 10:26 PM EDT
Completed Phase 4 Interventional Results available

A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia

NCT03110315
View directory record Official record
Conditions
Multiple Sclerosis, Fatigue, Insomnia
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Theodore R. Brown, MD MPH
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 18, 2026, 10:26 PM EDT
Active, not recruiting Phase 2 Interventional

Sildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries

NCT04565925
View directory record Official record
Conditions
Spinal Cord Injuries, Urinary Incontinence
Interventions
Sildenafil Citrate, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
College Station, Texas • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 18, 2026, 10:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

NCT00042289
View directory record Official record
Conditions
HIV Infections
Interventions
atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2, darunavir/ritonavir dosage #3, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF w/cobicistat, TAF w/cobicistat or ritonavir, efavirenz, darunavir/cobicistat, lopinavir/ritonavir dosage #1, atazanavir/ritonavir/tenofovir dosage #1, rifampicin, ethambutol, isoniazid, pyrazinamide, kanamycin, amikacin, capreomycin, moxifloxacin, levoflaxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose INH, bedaquiline, clofazamine, delamanid, linezolid, pretomanid, ethinyl estradiol, etonogestrel implant, nevirapine, amprenavir, abacavir, lopinavir/ritonavir dosage #2, indinavir/ritonavir dosage #1, fosamprenavir/ritonavir, lopinavir/ritonavir dosage #3, atazanavir/ritonavir dosage #1, didanosine delayed release (Videx® EC), emtricitabine, tenofovir, nelfinavir dosage #1, tipranavir/ritonavir, lopinavir/ritonavir dosage #4, raltegravir, etravirine, maraviroc, atazanavir/ritonavir dosage #2, tenofovir/atazanavir/ritonavir dosage #2, nelfinavir dosage #2, indinavir/ritonavir dosage #2, rilpivirine, darunavir/ritonavir dosage #4
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
1,578 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2020
U.S. locations
39
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 18, 2026, 10:26 PM EDT
Completed Not applicable Interventional Results available

Babies Living Safe and Smokefree

NCT02602288
View directory record Official record
Conditions
Second Hand Tobacco Smoke, Nicotine Dependence
Interventions
Ask, Advise, Refer, Telebased tobacco counseling, Telebased nutrition counseling, Mobile phone smoking cessation application, Mobile phone nutrition application, Nicotine polacrilex
Behavioral · Device · Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years and older · Female only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 18, 2026, 10:26 PM EDT
Completed Phase 2 Interventional Results available

Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma

NCT00737438
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 18, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting

NCT00622843
View directory record Official record
Conditions
HIV Infections, Streptococcus Pneumoniae
Interventions
pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine
Biological
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2013
U.S. locations
6
States / cities
San Diego, California • Washington D.C., District of Columbia • Tripler AMC, Hawaii + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 18, 2026, 10:26 PM EDT
Completed Phase 2 Interventional Results available

Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer

NCT00005908
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasm
Interventions
Docetaxel - Dose A, Anastrozole, cyclophosphamide, Docetaxel - Dose B, Doxorubicin hydrochloride, Tamoxifen Citrate, Capecitabine - Dose B, Capecitabine - Dose A
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Oct 18, 2026, 10:26 PM EDT
Withdrawn Not applicable Interventional

Is Topiramate Effective in Treating Dizziness in Patient's With Migraine-Associated Dizziness

NCT00732108
View directory record Official record
Conditions
Migraine, Headache, Dizziness
Interventions
topiramate, lactulose placebo pill
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 18, 2026, 10:26 PM EDT
Completed Phase 2 Interventional Results available

A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD

NCT03459040
View directory record Official record
Conditions
Graft-versus-host-disease, GVHD
Interventions
Alpha 1-Antitrypsin
Drug
Lead sponsor
John Levine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Duarte, California • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 18, 2026, 10:26 PM EDT
Completed Not applicable Interventional

Modified Atkins Diet Plus KetoCal for Adult Epilepsy

NCT01834482
View directory record Official record
Conditions
Epilepsy, Seizure, Medically Resistant Epilepsy, Medically Resistant Seizures
Interventions
Modified Atkins diet, KetoCal
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 18, 2026, 10:26 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

NCT00387959
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, rituximab, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Oct 18, 2026, 10:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Low and Moderate Fat Diets on Lipids, Inflammation and Vascular Reactivity in the Metabolic Syndrome

NCT00362908
View directory record Official record
Conditions
Metabolic Syndrome X, Dyslipidemias
Interventions
Moderate Fat and Moderate Carbohydrate Diet, Low Fat and High Carbohydrate Diet
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
30 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 28, 2010 · Synced Oct 18, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Results available

Docetaxel in Breast Cancer

NCT00312208
View directory record Official record
Conditions
Breast Cancer
Interventions
Docetaxel,doxorubicin, cyclophosphamide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
3,299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 30, 2013 · Synced Oct 18, 2026, 10:26 PM EDT
Completed Early Phase 1 Interventional

Early Anti-inflammatory Treatment in Patients With Acute ACL Tear and Painful Effusions

NCT03429140
View directory record Official record
Conditions
Anterior Cruciate Ligament
Interventions
Gel-One, Saline Placebo
Drug · Other
Lead sponsor
Cale Jacobs, PhD
Other
Eligibility
14 Years to 33 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 18, 2026, 10:26 PM EDT
Completed Not applicable Interventional Results available

Effect of Low Carbohydrate Versus Low Fat Diet in the Treatment of Dyslipidemia in Obese Children With Metabolic Syndrome

NCT03937960
View directory record Official record
Conditions
Metabolic Syndrome, Obesity, Dyslipidemias
Interventions
Carbohydrate restricted group, Standard low fat diet
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
10 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 18, 2026, 10:26 PM EDT
Completed Phase 1 Interventional

Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia

NCT01031368
View directory record Official record
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Acute Promyelocytic Leukemia (M3), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
cytarabine, clofarabine, filgrastim, Ex-vivo expanded cord blood progenitor cell infusion, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
Nohla Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 18, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

NCT01322490
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
PROSTVAC-V, PROSTVAC-F, GM-CSF, GM-CSF Placebo, Placebo
Biological · Drug · Other
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
84
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Berkeley, California + 68 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 18, 2026, 10:26 PM EDT
Not listed Phase 3 Interventional

Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma

NCT00816959
View directory record Official record
Conditions
Hodgkin's Lymphoma
Interventions
R-mabHDI and ABVD, ABVD
Drug
Lead sponsor
American Scitech International
Other
Eligibility
16 Years to 65 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
East Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 18, 2026, 10:26 PM EDT
Completed Phase 2 Interventional Results available

Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants

NCT02243202
View directory record Official record
Conditions
Obesity
Interventions
Canagliflozin, Phentermine, Matching Placebo to Canagliflozin, Matching Placebo to Phentermine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Phoenix, Arizona • Walnut Creek, California • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 18, 2026, 10:26 PM EDT